mergers & acquisitions

The deal will join CGI's portfolio of cancer tests and lab services with NovellusDx's technologies for cancer treatment response prediction.

The agreements involve the commercialization of the NeuMoDx 288 and 96 platforms for fully integrated, sample-to-answer, PCR-based molecular diagnostic testing.

The BD business, which has annual revenues of about $100 million, offers technical services as well as peptones for cell culture media used in biopharmaceutical applications.

Solana, founded in 2017 by former Illumina employees, has launched hundreds of products, including DNA sequencing solutions.

10x plans to use Epinomics' epigenomic technology to launch a single-cell ATAC solution on its Chromium platform by the end of the year.

Bruker plans to acquire an 80 percent stake in Hain, which has capabilities in tuberculosis and mycobacteria testing as well as virology and human genetics.

The company said it saw record-setting growth in new products in fiscal 2018 with increasing reimbursement adding to its hereditary cancer business.

According to Caprion, the company plans to use Primity's assets to expand its existing immunology and molecular profiling business.

Diagenode said the deal will bolster its suite of epigenomics services and platforms, as well as enhance its epigenetic biomarker discovery efforts.

The acquisition will enable Tecan to expand into the genomics space by coupling NuGen's NGS sample prep kits with its own laboratory automation products.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.